NCT01997944View on ClinicalTrials.gov

Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

November 30, 2014

Conditions
Chronic Hepatitis B
Interventions
BIOLOGICAL

Human Serum ALbumin/interferon alpha2a

600,750 or 900 mcg dosing every 2 weeks

BIOLOGICAL

Pegasys

180 mcg dosing every week

Trial Locations (1)

130021

Jilin University First Affiliated Hospital, Changchun

All Listed Sponsors
lead

Beijing Bio-Fortune Ltd.

INDUSTRY

NCT01997944 - Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients | Biotech Hunter | Biotech Hunter